Why Some Cannabis Users Get CHS — And Most Don’t with Codi Peterson

In this episode of Let’s Be Blunt with Montel, Montel sits down with pediatric pharmacist, clinical researcher, and patient-rights advocate Codi Peterson to explore one of the most discussed — and often misunderstood — topics in cannabis science: Cannabinoid Hyperemesis Syndrome (CHS).

Codi brings a unique perspective to the conversation, bridging clinical healthcare, public policy, and cannabis research. As a board member of Americans for Safe Access, Codi has been deeply involved in the fight for federal cannabis reform, patient access, and evidence-based cannabis education.

The discussion dives into Codi’s upcoming clinical research study surveying more than 1,100 individuals experiencing symptoms consistent with CHS, offering new insight into this emerging condition and how it is being interpreted in medicine and media.

Montel and Codi break down what CHS actually is, why it occurs in some individuals but not others, and how the lack of federal cannabis research has contributed to confusion, stigma, and misinformation around the topic.

The episode also explores the broader issues surrounding cannabis patient rights, physician education, harm-reduction strategies, and the future of cannabis medicine in the United States.

This is a thoughtful and science-driven conversation about how we can move beyond fear and misinformation toward responsible cannabis education and patient safety.

 

In This Episode

• What Cannabinoid Hyperemesis Syndrome (CHS) really is

• Why some heavy cannabis users experience cyclical vomiting

• What new research from a 1,100-person CHS survey reveals

• Why federal cannabis prohibition still blocks medical research

• The role of patient rights and advocacy in cannabis policy

• How physicians and pharmacists should approach cannabis education

• Why responsible cannabis use requires better public health information

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.